Michael Winkelmann
YOU?
Author Swipe
View article: Validation of SUV thresholds in [¹⁸F]SiTATE PET/CT for accurate meningioma segmentation
Validation of SUV thresholds in [¹⁸F]SiTATE PET/CT for accurate meningioma segmentation Open
Purpose Somatostatin receptor (SSTR)-targeted PET/CT provides valuable clinical insights beyond standard imaging in meningioma patients. Due to its excellent diagnostic capabilities and favorable logistics, the 18 F-labeled SSTR-targeting …
View article: Radiomics-based differentiation of upper urinary tract urothelial and renal cell carcinoma in preoperative computed tomography datasets
Radiomics-based differentiation of upper urinary tract urothelial and renal cell carcinoma in preoperative computed tomography datasets Open
Background To investigate a non-invasive radiomics-based machine learning algorithm to differentiate upper urinary tract urothelial carcinoma (UTUC) from renal cell carcinoma (RCC) prior to surgical intervention. Methods Preoperative compu…
View article: Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma
Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma Open
Background Despite revolutionary efficacy of CD19-CAR-T cell therapy (CAR-T) in aggressive B cell lymphoma, many patients still relapse mostly early. In early failure, distinct drugs support CAR-T which makes reliable and early prediction …
View article: ESR Essentials: imaging of lymphoma—practice recommendations by the European Society of Oncologic Imaging
ESR Essentials: imaging of lymphoma—practice recommendations by the European Society of Oncologic Imaging Open
Imaging is used for lymphoma detection, Ann Arbor/Lugano staging, and treatment response assessment. [ 18 F]FDG PET/CT should be used for most lymphomas, including Hodgkin lymphoma, aggressive/high-grade Non-Hodgkin lymphomas (NHL) such as…
View article: Predictive Value of Maximum Tumor Dissemination (Dmax) in Lymphoma Patients Treated with CD19 Specific CAR T-Cell Therapy
Predictive Value of Maximum Tumor Dissemination (Dmax) in Lymphoma Patients Treated with CD19 Specific CAR T-Cell Therapy Open
CD19 specific chimeric antigen receptor T-cell therapy (CART) has emerged as an effective treatment for relapsed or refractory (r/r) lymphoma. Imaging biomarkers are becoming increasingly important in risk assessment. The maximum distance …
View article: Supplementary Tables from Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy
Supplementary Tables from Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy Open
Supplementary Tables
View article: Supplementary Figures from Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy
Supplementary Figures from Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy Open
Supplementary Figures
View article: Supplementary Tables from Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy
Supplementary Tables from Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy Open
Supplementary Tables
View article: Supplementary Figures from Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy
Supplementary Figures from Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy Open
Supplementary Figures
View article: Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients
Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients Open
Background This study aimed to assess 68 Ga-DOTA-TATE (-TOC) PET/CT quantitative parameters in monitoring and predicting everolimus response in neuroendocrine tumor (NET) patients with hepatic metastases (NELM). Patients and methods This r…
View article: Liver-FDG-uptake and CAR T-cell kinetics augment early PET/CT prognostic value for CD19-targeted CAR T-cell therapy in diffuse large B cell lymphoma
Liver-FDG-uptake and CAR T-cell kinetics augment early PET/CT prognostic value for CD19-targeted CAR T-cell therapy in diffuse large B cell lymphoma Open
Despite revolutionary efficacy of CD19.CAR-T cell therapy (CAR-T) in aggressive B cell lymphoma, many patients still relapse mostly early. In early failure, distinct drugs support CAR-T which makes reliable and early prediction of imminent…
View article: Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors
Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors Open
Background This study explores the predictive and monitoring capabilities of clinical and multiparametric MR parameters in assessing capecitabine and temozolomide (CAPTEM) therapy response in patients with neuroendocrine tumors (NET). Pati…
View article: Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy Open
Purpose The emergence of chimeric antigen receptor (CAR) T-cell therapy fundamentally changed the management of individuals with relapsed and refractory large B-cell lymphoma (LBCL). However, real-world data have shown divergent outcomes f…
View article: Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM
Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM Open
Background This study aimed to evaluate the predictive and monitoring role of somatostatin receptor (SSTR) positron emission tomography-computed tomography (PET/CT) and clinical parameters in patients with neuroendocrine liver metastases (…
View article: Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy Open
Background Chimeric antigen receptor T-cell therapy (CART) is effective for patients with refractory or relapsed lymphoma with prolongation of survival. We aimed to improve the prediction of Lugano criteria for overall survival (OS) at 30-…
View article: Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors
Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors Open
Background Histopathology is the reference standard for diagnosing liver metastases of neuroendocrine tumors (NETs). Somatostatin receptor-positron emission tomography / computed tomography (SSR-PET/CT) has emerged as a promising non-invas…
View article: Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL Open
[Figure: see text]
View article: Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor–PET/CT
Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor–PET/CT Open
Purpose The aim of this study was to compare the diagnostic performance of different sets of MR sequences in detecting extrahepatic disease of NETs on routine liver magnetic resonance imaging (MRI). Method One hundred twenty-seven patients…
View article: Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors Open
Background Pseudoprogression (PsPD) is a rare response pattern to immune checkpoint inhibitor (ICI) therapy in oncology. This study aims to reveal imaging features of PsPD, and their association to other relevant findings. Methods Patients…
View article: Supplementary Tables from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
Supplementary Tables from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy Open
Supplementary Tables
View article: Supplementary Figures from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
Supplementary Figures from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy Open
Supplementary Figures
View article: Supplementary Tables from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
Supplementary Tables from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy Open
Supplementary Tables
View article: Supplementary Figures from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
Supplementary Figures from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy Open
Supplementary Figures